33 completed, 6 unknown, 4 terminated, 3 active not recruiting. 15 Phase 4, 11 Phase 3, 10 Phase 1, 5 Not applicable, 2 Phase 2.
Follow Desvenlafaxine Succinate: new trials by email Literature Review of Desvenlafaxine Succinate trials Research Report on Desvenlafaxine Succinate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Desvenlafaxine for Preventive Treatment of Frequent Migraines Desvenlafaxine, Placebo - Migraine | Not applicable | Active not recruiting | Tongji Hospital | 440 | 2026-01-01 | 2026-02-04 |
| Desvenlafaxine for Preventive Treatment of Frequent Episodic Tension-type Headache Desvenlafaxine, Placebo - Tension Type Headache | Not applicable | Active not recruiting | Tongji Hospital | 432 | 2025-12-01 | 2026-01-22 |
| The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia Pregabalin, Pregabalin with desvenlafaxine - Fibromyalgia, Pregabalin | Not applicable | Recruiting | Beijing Tiantan Hospital | 384 | 2025-09-15 | 2025-11-17 |
| A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats Fezolinetant, Paroxetine, Citalopram - Hot Flashes | Completed | Astellas Pharma Global Development, Inc. | 999 | 2023-11-15 | 2026-06-05 | |
| Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea Escitalopram, Paroxetine, Fluoxetine - Major Depression | Completed | Pfizer | 370212 | 2022-07-04 | 2024-12-09 | |
| Predictors of Cognitive Outcomes in Geriatric Depression Sertraline, bupropion, desvenlafaxine - Major Depressive Disorder, Neuroticism | Phase 4 | Active not recruiting | David Steffens | 75 | 2021-09-28 | 2026-05-22 |
| A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder SAGE-217, Matching Placebo, Sertraline - Depressive Disorder, Major | Phase 3 | Completed | Biogen | 440 | 2020-11-09 | 2023-12-22 |
| Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression Vortioxetine, Desvenlafaxine - Major Depressive Disorder | Phase 4 | Completed | H. Lundbeck A/S | 605 | 2020-06-18 | 2022-02-14 |
| A Study of MD-120 in Patients With Depression Desvenlafaxine 100 mg, Desvenlafaxine 50 mg, Placebo - Major Depressive Disorder | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 615 | 2020-05-18 | 2024-02-29 |
| A Relative Bioavailability Food Effect Study of LY03005 LY03005 - Major Depressive Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 34 | 2019-01-16 | 2019-08-06 |
| A Study of LY03005 vs Pristiq LY03005, Pristiq - Major Depressive Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 56 | 2018-06-19 | 2018-11-09 |
| Switching From SSRI to Desvenlafaxine on Cognitive Functioning Desvenlafaxine - Major Depressive Disorder | Unknown | Corporacion Parc Tauli | 36 | 2018-04-03 | 2019-04-18 | |
| Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® LY03005, Pristiq - Major Depressive Disorder | Phase 1 | Completed | Luye Pharma Group Ltd. | 20 | 2017-11-27 | 2018-01-04 |
| Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen Desvenlafaxine succinate 100mg, Desvenlafaxine succinate 50mg, Placebo - Hot Flashes, Breast Neoplasms | Phase 4 | Terminated | Seoul National University Hospital | 59 | 2017-11-10 | 2019-09-20 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function AL-335 800 mg, ODV 25 mg, SMV 75 mg - Hepatic Impairment | Phase 1 | Withdrawn | Janssen Research & Development, LLC | 2017-09-11 | 2017-10-11 | |
| Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment Desvenlafaxine - Depression, Anhedonia | Phase 4 | Completed | Unity Health Toronto | 56 | 2017-06-01 | 2020-11-02 |
| A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV) - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 59 | 2017-05-12 | 2017-11-14 |
| Pilot BA Study of New LY03005 vs Pristiq LY03005, Pristiq - Major Depression | Phase 1 | Completed | Luye Pharma Group Ltd. | 20 | 2016-12-07 | 2017-03-20 |
| Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies Lithium Carbonate, Lamotrigine, Valproic Acid - Bipolar Disorder | Terminated | University of New Mexico | 1037352 | 2016-09-01 | 2024-03-12 | |
| Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Desvenlafaxine, Placebo - Major Depressive Disorder | Phase 4 | Unknown | University of Calgary | 61 | 2014-12-01 | 2015-01-05 |
Showing 20 of 48. Sign in to see all of them.
Depressive Disorder, Major (28) · Depression (9) · Depressive Disorder (4) · Hot Flashes (3) · Mental Disorders (3) · Mood Disorders (3) · Dysthymic Disorder (2) · Generalized Anxiety Disorder (2) · Phobia, Social (2) · Acute Kidney Injury (1) · Anhedonia (1) · Anxiety Disorders (1) · Behavior, Addictive (1) · Bipolar Disorder (1) · Breast Neoplasms (1)
Pfizer (11) · Luye Pharma Group Ltd. (5) · Janssen Research & Development, LLC (2) · Tongji Hospital (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Astellas Pharma Global Development, Inc. (1) · BC Women's Hospital & Health Centre (1) · Beijing Tiantan Hospital (1) · Biogen (1) · Canadian Network for Observational Drug Effect Studies, CNODES (1) · Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal (1) · Centre for Addiction and Mental Health (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Corporacion Parc Tauli (1) · David Steffens (1)
United States (21) · Canada (14) · Estonia (4) · Latvia (4) · Slovakia (4) · China (3) · Finland (3) · France (3) · Lithuania (3) · Poland (3) · South Africa (3) · South Korea (3) · Belgium (2) · Croatia (2) · Japan (2)
Amy Sun, MD, PhD, MBA (2) · Wensheng Qu (2) · Arun Ravindran, MD, PhD (1) · Boadie W Dunlop, MD (1) · Bong-Jin Hahm, M.D., Ph.D. (1) · Christophe G Lambert, PhD (1) · Claudio N Soares, MD, PhD (1) · Corina Velehorschi, MD (1) · David J Hellerstein, MD (1) · David Steffens, M.D., M.H.S. (1) · Didier Jutras-Aswad, M.D., M.Sc. (1)
PMID 25758058, PMID 26644956, PMID 26709542, PMID 34183490, PMID 24571916, PMID 29140227, PMID 20616670, PMID 21977353, PMID 23010882, PMID 23266839, PMID 23266840, PMID 23473348, PMID 24229754, PMID 24583567, PMID 25012446, PMID 25375652, PMID 25860107, PMID 26137355, PMID 26231193, PMID 26693033, PMID 27009044, PMID 27280963, PMID 28763344, PMID 28901625, PMID 29738425, PMID 29920885, PMID 30423468, PMID 30508090, PMID 30583256, PMID 30986735, PMID 31237566, PMID 31651956, PMID 31744781, PMID 33688834, PMID 35592490, PMID 36996664, PMID 37227402, PMID 37875578, PMID 39019875, PMID 40108685, PMID 40456468, PMID 42214294
R01MH108578 (1)